Biofrontera Inc.
BFRI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $37,303 | $34,071 | $28,674 | $24,100 |
| % Growth | 9.5% | 18.8% | 19% | – |
| Cost of Goods Sold | $18,607 | $17,444 | $15,185 | $12,742 |
| Gross Profit | $18,696 | $16,627 | $13,489 | $11,358 |
| % Margin | 50.1% | 48.8% | 47% | 47.1% |
| R&D Expenses | $2,089 | $77 | $0 | $0 |
| G&A Expenses | $0 | $37,702 | $35,870 | $37,209 |
| SG&A Expenses | $33,835 | $39,127 | $35,870 | $37,209 |
| Sales & Mktg Exp. | $0 | $1,425 | $0 | $0 |
| Other Operating Expenses | $0 | $100 | -$3,800 | -$650 |
| Operating Expenses | $35,924 | $39,304 | $32,070 | $36,559 |
| Operating Income | -$17,210 | -$22,677 | -$18,581 | -$25,201 |
| % Margin | -46.1% | -66.6% | -64.8% | -104.6% |
| Other Income/Exp. Net | -$527 | $2,560 | $17,973 | -$12,456 |
| Pre-Tax Income | -$17,737 | -$20,117 | -$608 | -$37,657 |
| Tax Expense | $22 | $14 | $32 | $56 |
| Net Income | -$17,759 | -$20,131 | -$640 | -$37,713 |
| % Margin | -47.6% | -59.1% | -2.2% | -156.5% |
| EPS | -3.22 | -13.02 | -0.61 | -44.1 |
| % Growth | 75.3% | -2,034.4% | 98.6% | – |
| EPS Diluted | -3.22 | -13.02 | -0.61 | -44.1 |
| Weighted Avg Shares Out | 5,516 | 1,546 | 1,057 | 855 |
| Weighted Avg Shares Out Dil | 5,516 | 1,546 | 1,057 | 855 |
| Supplemental Information | – | – | – | – |
| Interest Income | $30 | $132 | $175 | $16 |
| Interest Expense | $2,106 | $600 | $370 | $360 |
| Depreciation & Amortization | $1,149 | $1,064 | $1,172 | $540 |
| EBITDA | -$14,441 | -$18,453 | $934 | -$36,757 |
| % Margin | -38.7% | -54.2% | 3.3% | -152.5% |